I am certain that many in my generation are familiar with the following words: “Raindrops on roses and whiskers on kittens/ Bright copper kettles and warm woolen mittens.” For the youngsters, those are lyrics from “My Favorite Things,” from the Broadway musical “The Sound of Music.” The song…
There are currently up to 18,000 people living with amyotrophic lateral sclerosis (ALS) in the U.S., with national costs likely to reach $1.02 billion each year, a study has found. Researchers also observed that men, white people, and veterans appear more likely to develop the disease. “However, large-scale, population-based…
The other evening, our daughter, Sara, read “Bread and Jam for Frances” aloud while I finished feeding dinner to my husband, Todd. He used to read this children’s book about a young badger with human qualities to Sara when she was little. In the book, Frances has an…
NeuroSense Therapeutics has joined researchers at Massachusetts General Hospital to study the impact of its investigational therapy PrimeC on key amyotrophic lateral sclerosis (ALS) processes. The collaboration will the headed by Ghazaleh Sadri-Vakili, director of the Neuroepigenetics laboratory at the MassGeneral Institute for Neurodegenerative Disease. Using a new…
Radicava (edaravone) is an approved infusion therapy used to slow functional decline in people with amyotrophic lateral sclerosis (ALS).
Exservan (riluzole oral film) is an approved oral treatment for amyotrophic lateral sclerosis (ALS). The medication can increase survival without the need for a tracheostomy — a tube inserted through the neck into the windpipe to help with breathing.
The ALS Society of Canada (ALS Canada) and Brain Canada are collaboratively investing CA$1.4 million (about $1.1M US) in nine grants for studies ranging from the development of new treatments for amyotrophic lateral sclerosis (ALS) to finding ways to predict disease progression. The ALS Canada Discovery…
Cytokinetics announced that it is stopping COURAGE-ALS, a Phase 3 trial investigating oral reldesemtiv in treating people with amyotrophic lateral sclerosis (ALS), due to a lack of efficacy compared with a placebo. In a review of unblinded interim trial findings at a second planned data monitoring committee meeting,…
The other day my husband, Todd, told me he forgot to ask the caregiver to spray out his clicker tube for his HeadMouse. Because he’s paralyzed from ALS, he clicks his computer mouse by sipping and puffing on a straw, and we only need to replace it once…
Tiglutik (riluzole oral suspension) is a liquid formulation of riluzole approved for treating amyotrophic lateral sclerosis (ALS). The medication can slow disease progression, extending survival time or the need for a tracheostomy, which is when a breathing tube is inserted through the neck into the trachea.
